Trial
NCT03446638
iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes
UnknownWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of Florida
Collaborators
Gateway for Cancer Research; Cellworks Group Inc.
Condition
Myelodysplastic Syndromes
Intervention
FDA-approved drug or combination of drugs
Why stopped
administratively withdrawn
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-11